Stay updated with breaking news from Stig Hansen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Roche agreed to take over unlisted obesity drug developer Carmot Therapeutics for $2.7 billion upfront, joining a list of contestants seeking to challenge the dominant makers of weight-loss drugs Novo Nordisk and Eli Lilly.
For the Swiss drugmaker, deal marks a return to a GLP-1 field that it abandoned in 2018
Carmot Therapeutics isn’t the first company targeting both the GLP-1 and GIP receptors to treat metabolic diseases. But the company contends that biased signaling—activating certain pathways but not others—is key to setting its drugs apart from others in the same class.
The AI revolution brings promise, not peril
In response to the increasing use of AI images, Google Deep Mind announced a beta version of SynthID. The tool will watermark and identify AI-Generated images. I